JUPITER, Fla. - Dyadic International , Inc. (NASDAQ: NASDAQ:DYAI), a global biotechnology company, has announced the publication of a study in Nature Communications demonstrating the effectiveness of a human monoclonal antibody produced using its proprietary C1-expression system.
The study, led by Prof. Albert Osterhaus of Hannover University of Veterinary Medicine and CR2O, a Dutch CRO, showed that the antibody, named HuMab 87G7, provided protection against SARS-CoV-2 in hamster and nonhuman primate models.
The research indicated that HuMab 87G7, developed through Dyadic's C1 technology, could be used for both prophylactic and therapeutic purposes without causing enhanced virus replication. This development comes at a crucial time, given the global concerns over emerging infectious diseases.
Mark Emalfarb, President and CEO of Dyadic, expressed confidence in the C1 platform's ability to rapidly produce human vaccines and antibodies, highlighting its potential for high yields, cost-effectiveness, and adaptability to new virus variants. Emalfarb also mentioned the platform's role in the company's first human vaccine clinical trial, DYAI-100, suggesting that the positive efficacy and safety data could accelerate the adoption of C1 technology in various health applications.
Dyadic's C1 system utilizes the fungus Thermothelomyces heterothallica to produce proteins at a commercial scale for human and animal health markets. The company also has developed the Dapibus platform for non-pharmaceutical applications, such as food and nutrition.
This news is based on a press release statement from Dyadic International, Inc.
InvestingPro Insights
As Dyadic International, Inc. (NASDAQ: DYAI) makes strides with its C1-expression system in biotechnology, the financial health and market performance of the company provide a broader context for investors. According to real-time data from InvestingPro, Dyadic boasts a market capitalization of $47.25 million. Despite not being profitable over the last twelve months, the company holds a significant Price / Book multiple of 6.17, indicating a premium market valuation relative to its net asset value as of Q1 2023.
InvestingPro Tips highlight that Dyadic holds more cash than debt on its balance sheet and has liquid assets that exceed short-term obligations. These factors suggest a stable financial position that could support ongoing research and development efforts. Furthermore, the company's strong return over the last month, with a 14.69% one-month price total return, reflects investor optimism following recent developments.
For those interested in a deeper dive into Dyadic's financials and performance metrics, InvestingPro offers additional tips for a comprehensive analysis. Currently, there are five more InvestingPro Tips available for DYAI, which can be accessed at https://www.investing.com/pro/DYAI. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enhancing your investment research toolkit.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.